



**ASX Announcement | 24 February 2021
Noxopharm Limited (ASX:NOX)**

Company Announcement Regarding Appendix 3Y Disclosures

24 February 2021 Sydney, Australia: The Board of Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX) advises that Noxopharm Founder and CEO, Dr Graham Kelly, through his associated entity, Milligene Pty Ltd (atf The GE and PR Kelly Family Trust):

- has sold 8,840,000 shares; and
- the sale was made via an on-market crossing after 4pm AEDT 23rd February 2021 at 65 cents to overseas institutional investors.

The primary purpose of the abovementioned sale is to fund the exercise of pre-IPO investor options that expire on 28th February 2021.

Following the share sale and option exercise, Dr Kelly will remain the Company's largest shareholder with a number of associated family entities - a position that he intends to maintain into the future. He also intends to continue as CEO to drive and escalate the Company's activities as it enters an important commercial phase.

The relevant Appendix 3Y and Form 604 for the sale transaction referred to above have also been released this morning. The Appendix 3Y and Form 604 for the option exercise transaction will be released once these shares have been allotted by the Company, and no later than Monday 1 March 2021.

-ENDS-

Mr Fred Bart, Non-Executive Chairman of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome/septic shock.

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda® has two main drug actions – indirect inhibition of sphingosine kinase and STING signaling. The former function contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. The latter



function provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also blocking the cytokine release syndrome.

Noxopharm also is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR).

To learn more, please visit: noxopharm.com

Investor & Corporate enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Media Enquiries

Julia Maguire

The Capital Network

E: julia@thecapitalnetwork.com.au

T: + 61 2 8999 3699

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.